Loading…
Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma
Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos. Since the recent discovery that serum mesothelin is a sensitive and highly specific biomarker for mesothelioma, one of the key issues raised is whether mesothelin levels represent a usefu...
Saved in:
Published in: | Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2010-09, Vol.19 (9), p.2238-2246 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c535t-4dfeaed8d69e1aa33db332ab1df498ff678fe20cf72bc00b9aea19b52e550ac33 |
---|---|
cites | cdi_FETCH-LOGICAL-c535t-4dfeaed8d69e1aa33db332ab1df498ff678fe20cf72bc00b9aea19b52e550ac33 |
container_end_page | 2246 |
container_issue | 9 |
container_start_page | 2238 |
container_title | Cancer epidemiology, biomarkers & prevention |
container_volume | 19 |
creator | CREANEY, Jenette OLSEN, Nola J BRIMS, Fraser DICK, Ian M MUSK, Arthur W DE KLERK, Nicholas H SKATES, Steven J ROBINSON, Bruce W. S |
description | Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos. Since the recent discovery that serum mesothelin is a sensitive and highly specific biomarker for mesothelioma, one of the key issues raised is whether mesothelin levels represent a useful screening test for asbestos-exposed at-risk individuals. In this study, soluble mesothelin was determined in sequential serum samples collected from asbestos-exposed individuals before the development of mesothelioma.
Archival serum samples from 106 individuals who developed mesothelioma, 99 asbestos-exposed individuals from the Wittenoom Cancer Surveillance Program, and 109 non-asbestos-exposed individuals from the Busselton Health Survey were identified. Serum mesothelin concentrations were determined using the MESOMARK assay.
Longitudinal mesothelin levels determined in healthy asbestos-exposed individuals over a period of 4 years were stable (Pearson's r = 0.96; P < 0.0001). There was no correlation between mesothelin concentration and cumulative asbestos exposure. Mesothelin concentrations were greater than the threshold value of 2.5 nmol/L in the penultimate serum sample before the diagnosis of mesothelioma in 17 of 106 people. Using an increase above the 95% confidence interval of the mean of a given individual's longitudinal mesothelin results, 33 of 82 individuals had increasing mesothelin levels before diagnosis.
In a population with a high pretest probability of developing mesothelioma, the serum biomarker mesothelin is elevated in absolute terms in 15% and in relative terms in 40% of the group.
Future studies examining a combination of biomarkers could improve sensitivity of screening. |
doi_str_mv | 10.1158/1055-9965.epi-10-0346 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_759315690</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>759315690</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-4dfeaed8d69e1aa33db332ab1df498ff678fe20cf72bc00b9aea19b52e550ac33</originalsourceid><addsrcrecordid>eNqNkE1P5DAMhiME4mv3J4B6QXsqOE3dNkc0zMJIjFgJdq-VmzpQ1DZD0h7499uKgblysmU9r209QpxJuJQSiysJiLHWGV7ypoklxKDSbE8cS1RFnOeI-1P_yRyJkxBeASDXiIfiKIEMJeTZsfj3yH7sojUHN7xw2_SRdT5akm_foxse2AyN6yNno-tQcRhciFd9PRquowX1hn20prZ57qkfdjtcRz_EgaU28M9tPRV_fy-fFnfx_cPtanF9HxtUOMRpbZm4LupMsyRSqq6USqiStU11YW2WF5YTMDZPKgNQaWKSusKEEYGMUqfi18fejXdv4_Rg2TXBcNtSz24MZY5aScw0fINMISkQsonED9J4F4JnW25805F_LyWUs_ty9lrOXsvln9U8nd1PufPthbHquP5KfcqegIstQMFQa_1ksAk7TiUylZCq_yI1jf8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>754028506</pqid></control><display><type>article</type><title>Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma</title><source>EZB Free E-Journals</source><creator>CREANEY, Jenette ; OLSEN, Nola J ; BRIMS, Fraser ; DICK, Ian M ; MUSK, Arthur W ; DE KLERK, Nicholas H ; SKATES, Steven J ; ROBINSON, Bruce W. S</creator><creatorcontrib>CREANEY, Jenette ; OLSEN, Nola J ; BRIMS, Fraser ; DICK, Ian M ; MUSK, Arthur W ; DE KLERK, Nicholas H ; SKATES, Steven J ; ROBINSON, Bruce W. S</creatorcontrib><description>Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos. Since the recent discovery that serum mesothelin is a sensitive and highly specific biomarker for mesothelioma, one of the key issues raised is whether mesothelin levels represent a useful screening test for asbestos-exposed at-risk individuals. In this study, soluble mesothelin was determined in sequential serum samples collected from asbestos-exposed individuals before the development of mesothelioma.
Archival serum samples from 106 individuals who developed mesothelioma, 99 asbestos-exposed individuals from the Wittenoom Cancer Surveillance Program, and 109 non-asbestos-exposed individuals from the Busselton Health Survey were identified. Serum mesothelin concentrations were determined using the MESOMARK assay.
Longitudinal mesothelin levels determined in healthy asbestos-exposed individuals over a period of 4 years were stable (Pearson's r = 0.96; P < 0.0001). There was no correlation between mesothelin concentration and cumulative asbestos exposure. Mesothelin concentrations were greater than the threshold value of 2.5 nmol/L in the penultimate serum sample before the diagnosis of mesothelioma in 17 of 106 people. Using an increase above the 95% confidence interval of the mean of a given individual's longitudinal mesothelin results, 33 of 82 individuals had increasing mesothelin levels before diagnosis.
In a population with a high pretest probability of developing mesothelioma, the serum biomarker mesothelin is elevated in absolute terms in 15% and in relative terms in 40% of the group.
Future studies examining a combination of biomarkers could improve sensitivity of screening.</description><identifier>ISSN: 1055-9965</identifier><identifier>EISSN: 1538-7755</identifier><identifier>DOI: 10.1158/1055-9965.epi-10-0346</identifier><identifier>PMID: 20651076</identifier><identifier>CODEN: CEBPE4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Asbestos - adverse effects ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Case-Control Studies ; Early Detection of Cancer - methods ; Female ; GPI-Linked Proteins - blood ; Humans ; Male ; Medical sciences ; Membrane Glycoproteins - blood ; Mesothelioma - blood ; Mesothelioma - etiology ; Mesothelioma - pathology ; Middle Aged ; Retrospective Studies ; Tumors</subject><ispartof>Cancer epidemiology, biomarkers & prevention, 2010-09, Vol.19 (9), p.2238-2246</ispartof><rights>2015 INIST-CNRS</rights><rights>(c)2010 AACR.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-4dfeaed8d69e1aa33db332ab1df498ff678fe20cf72bc00b9aea19b52e550ac33</citedby><cites>FETCH-LOGICAL-c535t-4dfeaed8d69e1aa33db332ab1df498ff678fe20cf72bc00b9aea19b52e550ac33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23214104$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20651076$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CREANEY, Jenette</creatorcontrib><creatorcontrib>OLSEN, Nola J</creatorcontrib><creatorcontrib>BRIMS, Fraser</creatorcontrib><creatorcontrib>DICK, Ian M</creatorcontrib><creatorcontrib>MUSK, Arthur W</creatorcontrib><creatorcontrib>DE KLERK, Nicholas H</creatorcontrib><creatorcontrib>SKATES, Steven J</creatorcontrib><creatorcontrib>ROBINSON, Bruce W. S</creatorcontrib><title>Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma</title><title>Cancer epidemiology, biomarkers & prevention</title><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><description>Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos. Since the recent discovery that serum mesothelin is a sensitive and highly specific biomarker for mesothelioma, one of the key issues raised is whether mesothelin levels represent a useful screening test for asbestos-exposed at-risk individuals. In this study, soluble mesothelin was determined in sequential serum samples collected from asbestos-exposed individuals before the development of mesothelioma.
Archival serum samples from 106 individuals who developed mesothelioma, 99 asbestos-exposed individuals from the Wittenoom Cancer Surveillance Program, and 109 non-asbestos-exposed individuals from the Busselton Health Survey were identified. Serum mesothelin concentrations were determined using the MESOMARK assay.
Longitudinal mesothelin levels determined in healthy asbestos-exposed individuals over a period of 4 years were stable (Pearson's r = 0.96; P < 0.0001). There was no correlation between mesothelin concentration and cumulative asbestos exposure. Mesothelin concentrations were greater than the threshold value of 2.5 nmol/L in the penultimate serum sample before the diagnosis of mesothelioma in 17 of 106 people. Using an increase above the 95% confidence interval of the mean of a given individual's longitudinal mesothelin results, 33 of 82 individuals had increasing mesothelin levels before diagnosis.
In a population with a high pretest probability of developing mesothelioma, the serum biomarker mesothelin is elevated in absolute terms in 15% and in relative terms in 40% of the group.
Future studies examining a combination of biomarkers could improve sensitivity of screening.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Asbestos - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Case-Control Studies</subject><subject>Early Detection of Cancer - methods</subject><subject>Female</subject><subject>GPI-Linked Proteins - blood</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins - blood</subject><subject>Mesothelioma - blood</subject><subject>Mesothelioma - etiology</subject><subject>Mesothelioma - pathology</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Tumors</subject><issn>1055-9965</issn><issn>1538-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqNkE1P5DAMhiME4mv3J4B6QXsqOE3dNkc0zMJIjFgJdq-VmzpQ1DZD0h7499uKgblysmU9r209QpxJuJQSiysJiLHWGV7ypoklxKDSbE8cS1RFnOeI-1P_yRyJkxBeASDXiIfiKIEMJeTZsfj3yH7sojUHN7xw2_SRdT5akm_foxse2AyN6yNno-tQcRhciFd9PRquowX1hn20prZ57qkfdjtcRz_EgaU28M9tPRV_fy-fFnfx_cPtanF9HxtUOMRpbZm4LupMsyRSqq6USqiStU11YW2WF5YTMDZPKgNQaWKSusKEEYGMUqfi18fejXdv4_Rg2TXBcNtSz24MZY5aScw0fINMISkQsonED9J4F4JnW25805F_LyWUs_ty9lrOXsvln9U8nd1PufPthbHquP5KfcqegIstQMFQa_1ksAk7TiUylZCq_yI1jf8</recordid><startdate>20100901</startdate><enddate>20100901</enddate><creator>CREANEY, Jenette</creator><creator>OLSEN, Nola J</creator><creator>BRIMS, Fraser</creator><creator>DICK, Ian M</creator><creator>MUSK, Arthur W</creator><creator>DE KLERK, Nicholas H</creator><creator>SKATES, Steven J</creator><creator>ROBINSON, Bruce W. S</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>20100901</creationdate><title>Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma</title><author>CREANEY, Jenette ; OLSEN, Nola J ; BRIMS, Fraser ; DICK, Ian M ; MUSK, Arthur W ; DE KLERK, Nicholas H ; SKATES, Steven J ; ROBINSON, Bruce W. S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-4dfeaed8d69e1aa33db332ab1df498ff678fe20cf72bc00b9aea19b52e550ac33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Asbestos - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Case-Control Studies</topic><topic>Early Detection of Cancer - methods</topic><topic>Female</topic><topic>GPI-Linked Proteins - blood</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins - blood</topic><topic>Mesothelioma - blood</topic><topic>Mesothelioma - etiology</topic><topic>Mesothelioma - pathology</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CREANEY, Jenette</creatorcontrib><creatorcontrib>OLSEN, Nola J</creatorcontrib><creatorcontrib>BRIMS, Fraser</creatorcontrib><creatorcontrib>DICK, Ian M</creatorcontrib><creatorcontrib>MUSK, Arthur W</creatorcontrib><creatorcontrib>DE KLERK, Nicholas H</creatorcontrib><creatorcontrib>SKATES, Steven J</creatorcontrib><creatorcontrib>ROBINSON, Bruce W. S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CREANEY, Jenette</au><au>OLSEN, Nola J</au><au>BRIMS, Fraser</au><au>DICK, Ian M</au><au>MUSK, Arthur W</au><au>DE KLERK, Nicholas H</au><au>SKATES, Steven J</au><au>ROBINSON, Bruce W. S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma</atitle><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><date>2010-09-01</date><risdate>2010</risdate><volume>19</volume><issue>9</issue><spage>2238</spage><epage>2246</epage><pages>2238-2246</pages><issn>1055-9965</issn><eissn>1538-7755</eissn><coden>CEBPE4</coden><abstract>Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos. Since the recent discovery that serum mesothelin is a sensitive and highly specific biomarker for mesothelioma, one of the key issues raised is whether mesothelin levels represent a useful screening test for asbestos-exposed at-risk individuals. In this study, soluble mesothelin was determined in sequential serum samples collected from asbestos-exposed individuals before the development of mesothelioma.
Archival serum samples from 106 individuals who developed mesothelioma, 99 asbestos-exposed individuals from the Wittenoom Cancer Surveillance Program, and 109 non-asbestos-exposed individuals from the Busselton Health Survey were identified. Serum mesothelin concentrations were determined using the MESOMARK assay.
Longitudinal mesothelin levels determined in healthy asbestos-exposed individuals over a period of 4 years were stable (Pearson's r = 0.96; P < 0.0001). There was no correlation between mesothelin concentration and cumulative asbestos exposure. Mesothelin concentrations were greater than the threshold value of 2.5 nmol/L in the penultimate serum sample before the diagnosis of mesothelioma in 17 of 106 people. Using an increase above the 95% confidence interval of the mean of a given individual's longitudinal mesothelin results, 33 of 82 individuals had increasing mesothelin levels before diagnosis.
In a population with a high pretest probability of developing mesothelioma, the serum biomarker mesothelin is elevated in absolute terms in 15% and in relative terms in 40% of the group.
Future studies examining a combination of biomarkers could improve sensitivity of screening.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>20651076</pmid><doi>10.1158/1055-9965.epi-10-0346</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1055-9965 |
ispartof | Cancer epidemiology, biomarkers & prevention, 2010-09, Vol.19 (9), p.2238-2246 |
issn | 1055-9965 1538-7755 |
language | eng |
recordid | cdi_proquest_miscellaneous_759315690 |
source | EZB Free E-Journals |
subjects | Adult Aged Aged, 80 and over Asbestos - adverse effects Biological and medical sciences Biomarkers, Tumor - blood Case-Control Studies Early Detection of Cancer - methods Female GPI-Linked Proteins - blood Humans Male Medical sciences Membrane Glycoproteins - blood Mesothelioma - blood Mesothelioma - etiology Mesothelioma - pathology Middle Aged Retrospective Studies Tumors |
title | Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T02%3A00%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20Mesothelin%20for%20Early%20Detection%20of%20Asbestos-Induced%20Cancer%20Malignant%20Mesothelioma&rft.jtitle=Cancer%20epidemiology,%20biomarkers%20&%20prevention&rft.au=CREANEY,%20Jenette&rft.date=2010-09-01&rft.volume=19&rft.issue=9&rft.spage=2238&rft.epage=2246&rft.pages=2238-2246&rft.issn=1055-9965&rft.eissn=1538-7755&rft.coden=CEBPE4&rft_id=info:doi/10.1158/1055-9965.epi-10-0346&rft_dat=%3Cproquest_cross%3E759315690%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c535t-4dfeaed8d69e1aa33db332ab1df498ff678fe20cf72bc00b9aea19b52e550ac33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=754028506&rft_id=info:pmid/20651076&rfr_iscdi=true |